Product Safety Recalls

Product Recall Tracker

LIFITEGRAST Recall D-0982-2022

Description: Xiidra (lifitegrast ophthalmic solution), packaged in a) 60 Single-Use Containers: 12 pouches x 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-12) and b) 5- Single-Use Containers (NDC 0078-0911-05) Rx Only, Manufactured by: The Ritedose Corporation, Columbia, SC 29203, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936.

LIFITEGRAST Recall D-0982-2022 Information

Mandated?Voluntary: Firm initiated
Recall NumberD-0982-2022
Event ID90176
Original Package?1
Active SubstanceLIFITEGRAST
DistributionNationwide within the United States
Quantity1,187,092 vials
Recall ReasonFailed Impurities/Degradation Specifications.
Drug ClassificationClass III
Drug Code Info20220615
Product NDC0078-0911
Product NUIN0000192701 N0000192700
Pharma Class (EPC)Lymphocyte Function-Associated Antigen-1 Antagonist [EPC]
Recall Initiation Date20220510
Report Date20220615
Classification Date20220606
Address1 Health Plz
East Hanover, NJ 07936-1016
United States
Recalling FirmNovartis Pharmaceuticals Corporation
Initial Notification Letter
Unique Ingredient Identifier038E5L962W
Drug Application NumberNDA208073
Structured Product Labeling (SPL ID)76e96acc-62cc-46d2-8478-32cb24ff36bb
Structured Product Labeling (SPL Set ID)8589d376-ac10-4ddb-9c53-2e0c8d5675c4
Similar To

© 2021 Recall.Report / Contact / Privacy Policy

This site's data is aggregated programmatically and provided "as is" without any representations or warranties, express or implied. is not affiliated with the Consumer Product Safety Commision, FDA, or US government in any way.